6533b832fe1ef96bd129aef3

RESEARCH PRODUCT

Impact of Treatment Failure on the Total Cost of Triple Therapy Including Boceprevir or Telaprevir Based on the French Early Access Program (ANRS CO20-CUPIC) Study

J.l. CallejaG. NoceaF. ChacónM.á SerraA. Valladares

subject

Pediatricsmedicine.medical_specialtyTotal costbusiness.industryHealth PolicyPublic Health Environmental and Occupational HealthTreatment failureTelaprevirchemistry.chemical_compoundchemistryBoceprevirmedicinebusinessmedicine.drug10.1016/j.jval.2013.08.164http://dx.doi.org/10.1016/j.jval.2013.08.164